Predicting survival for myeloid leukemia after HLA-identical sibling donor allogeneic stem cell transplantation
David Gallardo(Instituto Nacional de Cancerología), Juan José Berlanga(Centro de Biología Molecular Severo Ochoa), Antonio Jiménez(University of Miami), Jorge Sierra(Universitat Autònoma de Barcelona), Enric Carreras(Josep Carreras Leukaemia Research Institute), Cathrin Martin(Spanish Society of Hematology and Hemotherapy), Ildefonso Espigado(Instituto de Biomedicina de Sevilla), Guillermo Sanz(Instituto de Salud Carlos III), Armando Torres(California Institute of Technology), Rafael de la Cámara(Hospital Universitario de La Princesa), Juan Carlos Castrillón Vallejo(Spanish Society of Hematology and Hemotherapy), David Serrano(Hospital General Universitario Gregorio Marañón), César Sanz-Rodrı́guez(Merck Biopharma Co., Ltd. (Japan)), D. Caballero(Spanish Society of Hematology and Hemotherapy), Salut Brunet(Institut Català d'Oncologia)
Cited by 1
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k